Establishment Labs (NASDAQ:ESTA) Trading Down 5.3%

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) dropped 5.3% on Friday . The company traded as low as $49.28 and last traded at $49.80. Approximately 126,477 shares were traded during trading, a decline of 70% from the average daily volume of 428,203 shares. The stock had previously closed at $52.57.

Wall Street Analysts Forecast Growth

ESTA has been the subject of a number of recent analyst reports. Citigroup raised their price target on Establishment Labs from $49.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. raised their price target on Establishment Labs from $46.00 to $53.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Mizuho increased their price objective on Establishment Labs from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, April 1st. Finally, Stephens reiterated an "overweight" rating and issued a $47.00 price objective on shares of Establishment Labs in a research report on Thursday, January 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Establishment Labs presently has a consensus rating of "Buy" and a consensus target price of $55.00.

Establishment Labs Price Performance

The stock has a market capitalization of $1.30 billion, a P/E ratio of -15.59 and a beta of 1.24. The company has a debt-to-equity ratio of 10.26, a quick ratio of 1.67 and a current ratio of 3.06. The stock has a 50-day simple moving average of $46.93 and a 200 day simple moving average of $36.31.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.16. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The business had revenue of $31.60 million for the quarter, compared to analyst estimates of $31.44 million. During the same period last year, the company earned ($0.55) EPS. The firm's revenue was down 27.9% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs Holdings Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA boosted its position in shares of Establishment Labs by 3,244.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company's stock worth $41,000 after purchasing an additional 584 shares during the last quarter. Baker Avenue Asset Management LP bought a new position in Establishment Labs during the third quarter worth about $59,000. Global Retirement Partners LLC bought a new position in Establishment Labs during the third quarter worth about $60,000. Lazard Asset Management LLC lifted its holdings in Establishment Labs by 104.5% during the first quarter. Lazard Asset Management LLC now owns 963 shares of the company's stock worth $64,000 after acquiring an additional 492 shares in the last quarter. Finally, Deutsche Bank AG bought a new position in Establishment Labs during the fourth quarter worth about $66,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.